### Edgar Filing: HALOZYME THERAPEUTICS INC - Form 3/A

#### HALOZYME THERAPEUTICS INC

Form 3/A

February 11, 2005

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** 3235-0104 Number:

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

January 31, Expires:

Estimated average burden hours per

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

**SECURITIES** 

response... 0.5

2005

(Print or Type Responses)

1. Name and Address of Reporting

Person \*

Lim Jonathan E

(Last)

(First)

(Middle)

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Statement

(Month/Day/Year)

01/18/2005

4. Relationship of Reporting

Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year) 03/19/2004

(Check all applicable)

HALOZYME THERAPEUTICS INC [HTI]

C/O HALOZYME

THERAPEUTICS, INC., Â 1588 SORRENTO VALLEY RD.,

SUITE 17

(Street)

\_X\_ Director 10% Owner \_X\_ Officer Other

(give title below) (specify below) President, CEO

6. Individual or Joint/Group

Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

SAN DIEGO, CAÂ 92121

(City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

2. Amount of Securities Beneficially Owned

(Instr. 4)

Ownership Form:

4. Nature of Indirect Beneficial

Ownership (Instr. 5)

Direct (D) or Indirect

Â

(Instr. 5)

Common Stock

1. Title of Security

(Instr. 4)

484,497

D

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security

Conversion or Exercise

5. Ownership Form of

6. Nature of Indirect Beneficial Ownership

#### Edgar Filing: HALOZYME THERAPEUTICS INC - Form 3/A

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)
Warrants to Purchase Stock (2003 Bridge Financing)	10/20/2003	10/20/2007	Common Stock	26,690	\$ 0.4496	D	Â
Options to Purchase Common Stock	11/11/2003(1)	11/11/2013	Common Stock	2,214,791	\$ 0.39	D	Â

# **Reporting Owners**

Reporting Owner Name / Address	Keiauonsinps				
	Director	10% Owner	Officer	Other	
Lim Jonathan E					
C/O HALOZYME THERAPEUTICS, INC.	ÂΧ	Â	President, CEO	Â	

1588 SORRENTO VALLEY RD., SUITE 17 SAN DIEGO, CAÂ 92121

## **Signatures**

/s/ Jonathan E. 02/08/2005 Lim \*\*Signature of Date Reporting Person

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- 253,168 shares will be vested on 11/11/2003, 982,433 shares will be vested on 5/3/2004, 617,800 shares will be vested on 5/2/2005, 617,800 shares will be vested on 5/2/2006, contingent upon continued employment with of the Company

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2